RAD Completes Enrollment in Phase 2b Trial of RAD 101
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Interim results indicate a high level of concordance with MRI, which is the primary endpoint of the trial. This milestone highlights the progress of Radiopharm's radiopharmaceutical pipeline in addressing unmet medical needs in oncology.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Radiopharm Theranostics Limited on 6ix
Story so far
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
- RAD202 Phase 1 HEAT Trial Advances to Dose Level 3
- Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
- RAD Doses First Patient in RAD 402 Phase 1 Clinical Study
Later from Radiopharm Theranostics
- Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
- Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
- Radiopharm Theranostics Reports Business Update
- RAD Achieves Partial Response in Phase 1 Trial of RAD204
- Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics